It has been reported that the downregulation AMPK causes an increase in the activity of SREBP-1c and ACC which in turn leads to enhanced production and impaired catabolism of lipid and glucose in the liver which contributes to IR and dyslipidemia. This evidence concerns the gene SREBF1 and metabolic syndrome.